genericization love


from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. The process of becoming generic.
  • n. With respect to a trademark, becoming so widely identified as a reference for a type of product as to cease representing a particular manufacturer of a product of that type.


Sorry, no etymologies found.


  • Thermos was declared generic in the US in 1963 -- there's a good list of genericized trademarks at Wikipedia, as well as a discussion of the legal ramifications of genericization.

    genericized brand names: use a tissue, not a kleenex

  • Also, ‘genericization’ nice word, but I spell it with a z could have been done on such topics as replicability, public archiving of data and methods, and validity of proxies; invite the various authors of several multiproxy concoctions, and publish lists of who were invited, and who showed up.

    Sir Humphrey and the Boehlert Questions « Climate Audit

  • Few pharmaceutical houses don't face genericization of their blockbuster drugs.

    Google, Google, Google!

  • We are also pleased to see that management is actively pursuing in-licensing deals and acquisitions to make up for the loss of revenues that could take place with the genericization of Angiomax, which is facing patent challenges.

  • Moreover, genericization of key drugs is also expected to continue impacting sales adversely at Johnson & Johnson.

  • Moreover, we expect the top-and bottom-lines to remain under pressure from late 2011 as the contraction in lead product Zyprexa's (a treatment for schizophrenia and bipolar disorder) sales due to genericization will more than offset growth in Cymbalta (approved for treating depression), the diabetes franchise and sales of new products.

  • Bristol-Myers is looking to strengthen its product portfolio by launching new drugs to make up for the loss of revenues that is feared on the impending genericization of key drugs at Bristol-Myers, including the blockbuster blood-thinner Plavix.

  • Since the genericization of Xalatan, the LUMIGAN franchise has only been marginally affected in volume, given low copays in this market, physician concerns about the varying quality of generics and strong formula provisions for LUMIGAN.

  • In the U.S., our business is recovering from the effect of the generic of ALPHAGAN 0.15% and of and genericization of ACULAR, posting year-to-date acquisition dollar growth per SDI Health of 7.7% year-to-date in June and the branded ophthalmic market increased 5.7%.

  • Sales decreased 10.3% in dollars, which is attributable to the impact of the genericization of the original SANCTURA product.


Log in or sign up to get involved in the conversation. It's quick and easy.